Intensive Vasodilator Therapy in Patients With Essential Hypertension

• Status: Completed
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether add-on of intensive vasodilator therapy can improve the coronary perfusion and reduce the total peripheral resistance in patients with ongoing treatment for essential hypertension.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aarhus University Hospital
• Collaborator: University of Aarhus
• Treatments: Amlodipine; Lercanidipine; Losartan; Ramipril

Criteria

Inclusion Criteria:

• Ongoing antihypertensive treatment for >3 months

• Blood pressure >120/75 during antihypertensive treatment

• Ejection fraction > 45%

Exclusion Criteria:

• Blood pressure >160/100

• Pregnancy

• fertile women not using safe contraceptives

• known secondary hypertension

• valvular disease of haemodynamic significance

• known endocrine disease, nephropathy or hepatic disease

• present malignant disease

• known psychiatric disease

• abnormal lab tests of clinical significance

• known allergy to any study medication

• body mass index > 35

• Ongoing antihypertensive treatment with a combination of ACE-inhibitor and Calcium antagonist.